Hepatitis B vaccination in adults and children: temporary recommendations
About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

Public Health England
Wellington House
133-155 Waterloo Road
London SE1 8UG
Tel: 020 7654 8000
www.gov.uk/phe
Twitter: @PHE_uk
Facebook: www.facebook.com/PublicHealthEngland

For queries relating to this document, please contact: Immunisation.lead@phe.gov.uk

© Crown copyright 2017
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published July 2017
PHE publications gateway number: 2017223

PHE supports the UN
Sustainable Development Goals

Corporate member of Plain English Campaign
Committed to clearer communication

339

Issued 20/07/2017
Contents

Hepatitis B vaccination in adults and children: temporary recommendations

About Public Health England 2

Hepatitis B temporary recommendations for vaccine prioritisation and use during supply constraints 4

1.1 Vaccine recommendations ................................................................. 4
1.2 Vaccine options .............................................................................. 5
1.3 Prioritisation of groups ................................................................. 5
1.4 Vaccine supply and ordering .......................................................... 6
1.5 Advice tables .............................................................................. 6
Hepatitis B temporary recommendations for vaccine prioritisation and use during supply constraints

Hepatitis B immunisation temporary recommendations have been developed in light of recent global shortages of hepatitis B vaccine, including combination hepatitis A/B vaccine, which has severely impacted UK supply. These recommendations include temporary dose sparing advice to preserve adult and paediatric monovalent hepatitis B vaccine stock for those at highest immediate need and with the greatest ability to benefit.

1.1 Vaccine recommendations

Hepatitis B vaccine is highly effective in preventing infection if given prior to exposure following recommended schedules, but also is effective post exposure. Post exposure vaccination should start immediately, ideally within 24 hours of exposure. Risk groups for pre and post exposure immunisation and the routinely recommended schedules are detailed in chapter 18 of the Green Book.

1.1.2 Travel vaccine recommendations

The National Travel Health Network and Centre (NaTHNaC) provides hepatitis B immunisation recommendations for travellers. Risk for travellers is low although certain behaviours or activities put individuals at higher risk, particularly when these occur in areas where hepatitis B is more common. These behaviours and activities include:

- unprotected sex
- exposure to blood or blood products through occupation, such as healthcare work
- exposure to contaminated needles through injecting drug use, or as a result of accessing medical or dental care
- long stay travel

Please visit the NaTHNaC website for a full list of countries for which hepatitis B vaccine may be recommended prior to travel. A detailed risk assessment should be done on a case by case basis to determine whether vaccination against hepatitis B is actually indicated.

All travellers should also be reminded to avoid contact with blood and bodily fluids by:

- avoiding unprotected sexual intercourse.
- using appropriate protective precautions where contact is unavoidable e.g. due to occupation
- avoiding tattooing, piercing and acupuncture (unless sterile equipment is used)
- not sharing needles or other injection equipment.
- not sharing shaving equipment
Any traveller can be at risk of an accident or require emergency treatment. Travellers should be aware that using precautions will also help protect against other blood and body fluid-borne viruses (BBV), such as HIV and hepatitis C, for which there are currently no vaccines. A sterile medical equipment kit may be helpful when travelling to resource poor areas with high endemicity of hepatitis B.

Travellers should be informed about seeking advice, and consideration of post exposure, vaccination if they may have been exposed to hepatitis B.

1.2 Vaccine options

To mitigate the anticipated shortage of hepatitis B vaccine and to preserve adult and paediatric hepatitis B vaccine stock for those with the greatest ability to benefit, several alternative schedules and vaccine options can be considered.

Paediatric dosages are based on a lower dose of antigen needed to achieve an adequate immune response in children, rather than any concerns about safety. There are therefore no expected safety issues from using adult dose vaccines in children, which can be considered when paediatric vaccines are not available.

The advice is based on a broad assessment considering the following criteria:
- risk of acquiring infection
- risk of complications of infection
- immune response to vaccine products of varying antigen content
- vaccine availability and number of doses required
- compliance with vaccine schedule
- feasibility of delivery in settings
- likelihood of individual already being immune
- availability and effectiveness of non-vaccine preventative measures

Many of these vaccine options will be off-label use of licensed products. For further information on off-label use of vaccines see:
https://www.gov.uk/government/publications/off-label-vaccine-leaflets

1.3 Prioritisation of groups

For all pre and post exposure indications, an individual risk assessment is required. In general, the risk of acquiring infection from an exposure incident with a known infected source is higher than that from an unknown source or in most pre-exposure situations. Infants born to hepatitis B infected mothers are the highest priority for post-exposure vaccination as they are at greatest individual risk of infection; these infants have been exposed to a substantial amount of infected blood during the birthing process. In post-exposure situations where the source is unknown, urgent testing of the source should be conducted to inform the need for further vaccination of recipient. Guidance on post-exposure vaccination (including need for hepatitis B immunoglobulin) is found in the Green Book, Chapter 18, Hepatitis B.

The likelihood of acquiring infection following exposure is dependent on several factors including the hepatitis B status of source, or if unknown, the prevalence in the implicated
population, the hepatitis B immune status of recipient, the mechanism and route of transmission – whether is it a significant exposure, the likely infecting dose and/or volume of potentially infected blood/body fluid, and the immediacy of risk.

Where appropriate, patients should be advised of other precautions that are effective in protecting them against hepatitis B and non-vaccine preventable BBV such as HIV and hepatitis C. Precautions include using condoms during sex, and harm minimisation strategies for people who inject drugs (not sharing needles or injecting equipment, using needle and syringe exchange services, transitioning to opiate substitution therapies).

1.4 Vaccine supply and ordering

In the UK, licensed hepatitis B monovalent and combination hepatitis A/B vaccines are provided by Merck Sharp & Dohme Limited (MSD) or GlaxoSmithKline (GSK). These vaccines are not centrally procured or supplied by PHE. They should be ordered direct from manufacturers or wholesaler companies. PHE does not hold any emergency stockpile.

If your usual vaccine cannot be obtained from your usual supplier / manufacturer try an alternative supplier and/or an alternative vaccine. To register to become a customer of GSK or MSD visit http://www.aah.co.uk/shop/en-GB/aahpoint/opening-an-aah-account or telephone the AAH Customer Services number: 0344 561 8899, stating which company you would like to place an order for.

Providers are requested to exercise constraint in ordering vaccines and to observe manufacturers’ ordering restrictions; these have been introduced to a) prioritise vaccine for post exposure vaccination (particularly infants born to infected mothers); and b) to prevent stock from being exhausted rapidly. Where possible, providers should aim to order small quantities of stock frequently rather than large quantities for longer periods; please do not attempt to stockpile. Responsible ordering will help preserve stock for those at greatest need.

Manufacturers have put in processes to allow exceptional requests for additional doses if there is a clear clinical and public health need on an individual patient basis or as part of an outbreak response e.g. transmission event in a renal dialysis unit.

1.5 Advice tables

The tables below include advice for pre-exposure and post exposure prophylaxis and for completion of primary schedules and boosting. The advice provided is not absolute; it requires some clinical judgement and hence is not presented in an algorithm, but in tables. The advice will be updated as vaccine availability changes.

Table 1: Antigen content of hepatitis B containing vaccines available in the UK
Table 2: Prioritisation of groups for whom hepatitis B vaccination is considered
Table 3: Post exposure dose-sparing options for hepatitis B vaccination to preserve vaccine for groups most likely to benefit
Table 4: Pre-exposure dose-sparing options for hepatitis B vaccination to preserve vaccine for groups most likely to benefit
Table 5: Dose sparing options for completion of pre-exposure schedules and boosting

Issued 20/07/2017
Table 1 Antigen content of hepatitis B containing vaccines available in the UK

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Ages and group</th>
<th>Trade name</th>
<th>HepB vaccine antigen content (micrograms)</th>
<th>Volume (ml)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monovalent HepB</td>
<td>Paediatric: 0-15 years</td>
<td>Engerix®</td>
<td>10</td>
<td>0.5</td>
<td>GlaxoSmithKline (GSK)</td>
</tr>
<tr>
<td>Monovalent HepB</td>
<td>Paediatric: 0-15 years</td>
<td>HBVaxPRO®</td>
<td>5</td>
<td>1.0</td>
<td>Merck Sharp &amp; Dohme Limited (MSD)</td>
</tr>
<tr>
<td>Combination HepA/HepB</td>
<td>Paediatric: 1-15 years</td>
<td>Twinrix Paediatric®</td>
<td>10</td>
<td>0.5</td>
<td>GSK</td>
</tr>
<tr>
<td>Combination DTaP/IPV/Hib/HepB</td>
<td>Paediatric: 6 weeks -2 years</td>
<td>Infanrix hexa®</td>
<td>10</td>
<td>0.5</td>
<td>GSK</td>
</tr>
<tr>
<td>Monovalent HepB</td>
<td>Adult: 16 years and over</td>
<td>Engerix®</td>
<td>20</td>
<td>1.0</td>
<td>GSK</td>
</tr>
<tr>
<td>Monovalent HepB</td>
<td>Adult: 16 years and over</td>
<td>HBVaxPRO®</td>
<td>20</td>
<td>1.0</td>
<td>MSD</td>
</tr>
<tr>
<td>Combination HepA/HepB</td>
<td>Adult: 16 years and over</td>
<td>Twinrix Adult®</td>
<td>20</td>
<td>1.0</td>
<td>GSK</td>
</tr>
<tr>
<td>Monovalent HepB Renal high antigen content</td>
<td>Adult (15 years and over) renal pre-dialysis and dialysis patients</td>
<td>Fendrix®</td>
<td>20</td>
<td>0.5</td>
<td>GSK</td>
</tr>
<tr>
<td>Monovalent HepB Renal high antigen content</td>
<td>Adult renal pre-dialysis and dialysis patients</td>
<td>HBVaxPRO40®</td>
<td>40</td>
<td>1.0</td>
<td>MSD</td>
</tr>
</tbody>
</table>

Table 2 Prioritisation of individuals / groups

This prioritisation should not be followed rigidly but is provided to support decision-making on the basis of an assessment of the individual patient’s risk. Many specific factors may alter the prioritisation of the examples shown below including factors such as the recipient’s hepatitis B status (e.g. already has evidence of exposure), likely compliance with follow up, and access to post-exposure advice.

<table>
<thead>
<tr>
<th>Prioritisation</th>
<th>Exposure type</th>
<th>Comments / examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Highest risk and urgency</td>
<td>Post exposure – substantial exposure to infected blood from known positive case</td>
<td>Selective neonatal immunisation programme of infants born to hepatitis B infected mothers</td>
</tr>
<tr>
<td>2</td>
<td>Post exposure – other post exposure to a known hepatitis B infected source</td>
<td>Needlestick or other sharps injury from known positive person, sexual exposure to an acute case of hepatitis B</td>
</tr>
<tr>
<td>3</td>
<td>Post exposure to an unknown source OR Pre-exposure priming for unavoidable, high and imminent risk</td>
<td>Needlestick injury from discarded needle in community, sexual assault, mass casualties from a major incident Sex workers, MSM with multiple partners, PWID, prisoners, people travelling to endemic countries for medical treatment</td>
</tr>
<tr>
<td>4</td>
<td>Pre-exposure priming for those at lower risk or where risk may be avoided or delayed, and/or those that can access advice in the event of a recognised exposure</td>
<td>Household contacts of people with hepatitis B, renal dialysis patients, other travel to medium and high endemicity countries, occupational health in UK healthcare settings</td>
</tr>
<tr>
<td>5 Lowest risk and urgency</td>
<td>Pre-exposure --boosting / reinforcing doses</td>
<td>For healthy individuals who have completed a primary course of immunisation (three doses)</td>
</tr>
</tbody>
</table>

Issued 20/07/2017
Table 3  Post-exposure options for hepatitis B vaccination in adults and children (to be read in conjunction with Table 18.7 of the Green Book)

<table>
<thead>
<tr>
<th>Post-exposure vaccination</th>
<th>Order of preference</th>
<th>Infants born to hepatitis B infected mothers</th>
<th>Other children exposed to a known or unknown source of hepatitis B</th>
<th>Adults exposed to a known or unknown source of hepatitis B</th>
</tr>
</thead>
<tbody>
<tr>
<td>URGENT TESTING OF THE SOURCE, IF THEIR HEPATITIS B STATUS UNKNOWN, SHOULD BE DONE</td>
<td>1st</td>
<td>Paediatric monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
<td>Paediatric combination HepA/B vaccine (Twinrix paediatric)</td>
<td>Adult monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
</tr>
<tr>
<td>2nd</td>
<td>Adult monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
<td>High dose paediatric HepA/B vaccine (Ambirix)</td>
<td>High Ag content HepB vaccine (Fendrix or HBVaxPRO40)</td>
<td></td>
</tr>
<tr>
<td>3rd</td>
<td>Paediatric combination HepA/B vaccine (Twinrix paediatric)</td>
<td>Paediatric monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
<td>Adult combination HepA/B vaccine (Twinrix)</td>
<td></td>
</tr>
<tr>
<td>4th</td>
<td>High dose paediatric or adult combination HepA/HepB vaccine (Ambirix or Twinrix)</td>
<td>Adult monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
<td>High dose paediatric HepA/B vaccine (Ambirix)</td>
<td></td>
</tr>
<tr>
<td>5th</td>
<td>Combination DTaP/IPV/Hib/HepB* (Infanrix hexa)</td>
<td>Adult combination HepA/HepB vaccine (Twinrix)</td>
<td>Two simultaneous doses of paediatric combination HepA/B vaccine (Twinrix Paediatric)</td>
<td></td>
</tr>
</tbody>
</table>

Considerations /rationale/other advice
- A full risk assessment should be undertaken taking into account hepatitis B status of source, significance of exposure, vaccination status of recipient and indications for vaccine (+/- hepatitis B (HBIG)) given as recommended in Table 18.7 of the Green Book and Immunoglobulin Handbook.
- Urgent testing of the source, if unknown or uncertain hepatitis B status, should be done, preferably before vaccine is given; if source is negative, first or further doses may not be required – see table 18.7 in the Green Book.
- No immunogenicity data are available to support use of paediatric antigen content vaccine in adults post exposure.
- Vaccine administration should never be delayed for infants born to hepatitis B infected mothers, as these infants have been exposed to a substantial volume of infectious blood during the birthing process.
- Paediatric monovalent HepB vaccine is prioritised for infants born to hepatitis B infected mothers, so paediatric combination HepA/HepB vaccine is recommended for other post exposure indications in children. Combination DTP/IPV/Hib/HepB may be used from six weeks of age for second and subsequent doses.
*Exceptionally, DTP/IPV/Hib/HepB (licensed from 6 weeks of age) may be used from four weeks of age but should not count towards the routine infant schedule for the other antigens.
- High Ag content vaccine for renal indications can be used as post exposure in adults in preference to preserve adult normal Ag content monovalent or combination HepA/B vaccine for pre-exposure use or for post-exposure use in infants and children.
- Combination HepA/HepB vaccine for hepatitis A may be preferred if HepA vaccination also indicated e.g. MSM, travellers, chronic liver disease.
- Simultaneous doses of lower antigen content vaccines should be given at same site and are preferred to doses given separately to ensure compliance.
Table 4 Pre-exposure options for hepatitis B vaccination in children and adults

<table>
<thead>
<tr>
<th>Order of preference</th>
<th>Children</th>
<th>Immunocompetent adults</th>
<th>Adults with immunosuppression or chronic liver disease</th>
<th>Adults of any age with renal failure who are pre-dialysis or on dialysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>Paediatric combination HepA/B vaccine (Twinrix paediatric)</td>
<td>Adult monovalent HepB vaccine (unless requiring hepatitis A)</td>
<td>Adult combination HepA/B vaccine (Twinrix)</td>
<td>High Ag content HepB vaccine (Fendrix or HBVaxPRO40)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(EngerixB or HBVaxPRO)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2nd</td>
<td>Paediatric monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
<td>Adult combination HepA/B vaccine (Twinrix)</td>
<td>High dose paediatric HepA/B vaccine (Ambririx)</td>
<td>Adult monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Twinrix)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3rd</td>
<td>Adult monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
<td>High dose paediatric HepA/B vaccine (Ambririx)</td>
<td>Adult monovalent HepB vaccine (EngerixB or HBVaxPRO)</td>
<td>High dose paediatric or adult combination HepA/HepB vaccine (Ambririx or Twinrix)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Ambririx)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4th</td>
<td>High dose paediatric or adult combination HepA/HepB vaccine</td>
<td>Paediatric combination HepA/HepB vaccine (Twinrix paediatric)</td>
<td>Two simultaneous doses of paediatric combination HepA/HepB vaccine (Twinrix paediatric)</td>
<td>Two simultaneous doses of paediatric combination HepA/HepB vaccine (Twinrix paediatric)</td>
</tr>
<tr>
<td></td>
<td>(Ambirix or Twinrix)</td>
<td>(Twinrix paediatric)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Considerations /rationale/ other advice

- No immunogenicity data are available to support use of paediatric antigen content vaccine in adults pre-exposure.
- Paediatric combination HepA/B vaccine is preferred for pre-exposure use in children to preserve monovalent paediatric HepB vaccine for those infants born to infected mothers; children may also have a (future) indication for hepatitis A vaccine too (travel to endemic countries).
- Those who are older, immunocompromised (including HIV+) and have chronic liver disease may have a lower response to vaccine and are at higher risk of developing either chronic infection or serious complications.
- Combination HepA/HepB vaccine for hepatitis A may be preferred if hepatitis A is also indicated e.g. MSM, travellers, chronic liver disease.
- Simultaneous doses of lower antigen content vaccines should be given at same site and are preferred to doses given separately to ensure compliance.
- Renal dialysis patients are tested post vaccination and regularly; reinforcing doses can therefore be given if they have a suboptimal response to vaccine (see Green Book chapter 18).
- People travelling to high risk countries for long periods of time should be advised of usual precautions to protect against hepatitis B and other blood-borne viruses (HIV and hepatitis C) which are not preventable by vaccine but have similar transmission routes. (See section 1.1 above and NATHNAC for further advice).
- Workers at occupational risk should be aware of universal precautions to prevent hepatitis B infection and other blood-borne viruses (HIV and hepatitis C) which are not preventable by vaccine but have similar transmission routes.
- At–risk individuals, particularly those at occupational risk, should be advised to follow post-exposure local guidance in the event of a significant exposure (see also table 18.7 in chapter 18 of the Green Book).
Hepatitis B vaccination temporary recommendations

### Table 5 Dose sparing options for completion of pre-exposure schedules and for boosting

<table>
<thead>
<tr>
<th>Dose sparing option</th>
<th>Rationale / Examples</th>
<th>Other advice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Schedule options for pre-exposure primary immunisation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avoid using 0, 7, 21 day (super-accelerated) schedule - preferentially use standard (0, 1, 6 months) or, if rapid protection required, the accelerated schedule (0, 1, 2 months)</td>
<td>• The super-accelerated schedule uses 3 doses in 1 month which is wasteful in the current supply climate and because the immune response following 3 doses with the super accelerated schedule is lower than that with 3 doses of the standard or accelerated schedule, it makes deferral of the reinforcing/booster dose at 12 months more risky • For most indications, particularly travel and occupational health, there should be sufficient time to complete or start the standard or accelerated course • Limited data suggest that, in healthy adults over 18 years, two doses at 0 and 1 months will provide equivalent protection to 3 doses at the super-accelerated schedule</td>
<td>• Remind workers at occupational risk of universal precautions to prevent hepatitis B infection and other blood-borne viruses (HIV and hepatitis C) which are not preventable by vaccine but have similar transmission routes • Remind at –risk individuals, particularly those at occupational risk, to follow post-exposure local guidance in the event of a significant exposure (see also table 18.7 in chapter 18 of the Green Book) • Remind travellers of other precautions to prevent hepatitis B and other blood-borne viruses (HIV and hepatitis C) which are not preventable by vaccine but have similar transmission routes. (See section 1.1 above and NATHNAC for further advice)</td>
</tr>
<tr>
<td>Defer third dose of primary pre-exposure immunisation to at least 6 months in those not at immediate risk of exposure who can recognise exposure and access care promptly</td>
<td>• Equivalent protection achieved after 3 doses with 0, 1 6 month and 0,1,2 month schedules • In healthy adults and children, a high proportion will have started to respond after a second dose of hepatitis B vaccine and a completing dose given after an exposure should provide rapid protection.</td>
<td></td>
</tr>
<tr>
<td><strong>Boosting</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In immunocompetent individuals who have completed a primary immunisation course at 0, 1, 2 months, boosting can be deferred to 24 months</td>
<td>• Although knowledge about the duration of protection against infection and disease is still incomplete, studies demonstrate that, among successfully vaccinated immunocompetent individuals, protection against chronic infection persists for 20-30 years or more. Therefore WHO have concluded that there is no compelling evidence for recommending a booster dose of hepatitis B vaccine in routine immunisation programmes.</td>
<td></td>
</tr>
<tr>
<td>In immunocompetent healthcare and lab workers, who have completed a primary immunisation course, defer the single booster dose currently recommended five years after the primary course for at least another 12 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Other resources


- NaTHNaC list of countries for travel vaccination recommendations: [https://travelhealthpro.org.uk/countries](https://travelhealthpro.org.uk/countries)